SynBioBeta Speaker
Cindy Groff-Vindman
CINBIO
Founder
Dr. Cindy Groff-Vindman is a molecular geneticist and biotechnology executive focused on the transition of industrial biology from promising science to durable manufacturing businesses within the emerging bioeconomy. Her work sits at the intersection of synthetic biology, industrial biomanufacturing, and national security. Her recent publications explore how advances in AI-enabled bioengineering, industrial biotechnology, and secure biological data systems are reshaping the bioeconomy. She is particularly interested in the emergence of a new generation of industrial bio companies that combine scientific innovation with manufacturing discipline, capital efficiency, and customer-driven product development, as well as encouraging public investment in the infrastructure needed to enable safe, secure, and predictable bioengineering.She is the founder of CINBIO LLC, where she advises venture investors, corporations, and public–private partnerships on disciplined investment, technology readiness, and the operational realities of scaling biotechnology to deliver commercially viable materials and products. Dr. Groff-Vindman previously served as Government Chief Technology Officer for BioMADE, the Manufacturing Innovation Institute established to strengthen the U.S. bioindustrial economy. In that role she helped shape national technology investment strategy and advised on a portfolio of more than $300 million supporting dual-use biomanufacturing platforms, guiding programs from early research through industrial adoption.In government she worked end to end along the technology and acquisition lifecycle from basic research and technology maturation through procurement and fielded capability. She helped develop the U.S. Army’s synthetic biology strategy as an Associate Program Manager for emerging research programs and previously served as Lead Scientist for PM Soldier Clothing and Individual Equipment under PEO Soldier, delivering mission critical technologies. Her career spans biotechnology research and development, federal technology investment strategy, intellectual property, and international science diplomacy. She also served as an officer in the U.S. Army, bringing a perspective that integrates technical innovation, operational discipline, and national security considerations in emerging biological technologies.
